Good morning, everyone, and welcome to the middle of the week. Getting this far is an accomplishment, and so we are celebrating with a cup of stimulation. After all, consider the alternatives. Thankfully, the local water company is not drilling at our doorstep today, so we can attack our ever-growing to-do list. So time to get cracking. As always, we have assembled some tidbits for you to peruse. Have a productive day and do stay in touch …
A review by US Food and Drug Administration staffers questioned whether an experimental Merck drug is effective in treating Clostridium difficile, or C. difficile, the most common cause of infectious diarrhea in hospitals and nursing homes, Reuters writes. An FDA advisory panel meets Thursday to decide whether the drug should be recommended for approval.
Biogen suffered a setback as its first drug for repairing nerve damage in multiple sclerosis patients missed its primary goal in a mid-stage study, the Boston Globe writes. The failure cut its market value by more than $7 billion Tuesday because the drug maker wants to shift its R&D to treatments that can reverse the disease, not just slow its progression.
About the Author Reprints
